Feb 28 |
(CTLT) - Analyzing Catalent's Short Interest
|
Feb 26 |
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
|
Feb 14 |
Catalent gains after filing 10-Q
|
Feb 14 |
Nearly Half Of S&P 500 Stocks Trade Below 50-Day Moving Average: Which One Is The Cheapest?
|
Feb 10 |
Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited
|
Feb 9 |
FTC likely to look at Catalent alternatives in review of Novo deal - report
|
Feb 9 |
Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down
|
Feb 9 |
Catalent (CTLT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
|
Feb 9 |
UPDATE 3-Catalent sales edge past estimates as focus shifts to Novo deal
|
Feb 9 |
Catalent Inc (CTLT) Faces Headwinds with Q2 Fiscal 2024 Results
|